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Abstract
Background: Carcinoma of unknown primary tumors (CUP) is present in 0.5%-9% of all patients with malignant
neoplasms; only 20%-27% of primary sites are identified before the patients die. Currently, 18F-fluorodeoxy-glucose
positron-emission tomography (18F-FDG PET) or PET combined with computed tomography (PET/CT) is widely
used for the diagnosis of CUP. However, the diagnostic yield of the primary site varies. The aim of this study was
to determine whether PET or PET/CT has additional advantages over the conventional diagnostic workup in
detecting the primary origin of CUP.
Findings: Twenty patients with unknown primary tumors that underwent PET or PET/CT were included in this
study. For all patients, the conventional diagnostic workup was unsuccessful in detecting the primary sites. Among
20 patients, 11 had PET scans. The remaining nine patients had PET/CT. In all 20 patients, neither the PET nor PET/
CT identified the primary site of the tumor, including six cases with cervical lymph node metastases. The PET and
PET/CT revealed sites of FDG uptake other than those associated with known metastases in seven patients, but
these findings did not influence patient management or therapy. Two patients had unnecessary invasive diagnostic
procedures due to false positive results on the PET or PET/CT.
Conclusions: Although it is inconclusive because of small sample size of the study, the additional value of PET or
PET/CT for the detection of primary sites in patients with CUP might be less than expected; especially in patients
that have already had extensive conventional diagnostic workups. Further study is needed to confirm this finding.
Introduction
Carcinoma of unknown primary tumors (CUP) is a
biopsy-proven malignancy in which the anatomical ori-
gin of the tumor cannot be identified from the patient
history, physical examination, laboratory testing, chest
radiographs, computed tomography of the chest, abdo-
men and pelvis, and (in women) mammography [1].
CUP is present in 0.5-9% of patients with malignant
neoplasms; however, only 20-27% of primary sites are
identified before the patients die [2]. Some studies have
reported that although the median survival time of
patients with CUP is less than 1 year, if the primary site
is identified and specific therapy started, the survival
time can be increased [3,4]. However, primary tumors
are detected in less than 40% of patients by conventional
diagnostic procedures, even when multiple examinations
are performed [1].
Currently, positron-emission tomography (PET) with
18F-fluorodeoxyglucose (FDG) or PET combined with
computed tomography (PET/CT) is widely used in the
diagnostic evaluation of patients with CUP [5]. The rate
of detection of the primary site varies; 24.5-41% for the
FDG-PET [6,7] and 22-73% with the FDG-PET/CT [8].
These variable diagnostic yields might be due to differ-
ent patient inclusion criteria and the extent of the diag-
nostic workup in different studies. Therefore, the
efficacy of PET or PET/CT for the detection of primary
sites in patients with CUP remains to be determined.
Furthermore, there is concern about the false positive
PET results in regions endemic for TB [9]. Therefore,
the aim of this study was to determine whether PET or
PET/CT had additional advantages over conventional
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gin of CUP.
Methods
Patients
The medical records of patients with CUP that under-
went PET or PET/CT imaging were reviewed retrospec-
tively. All patients were admitted to the Seoul National
University Hospital for further evaluation between
January 2003 and September 2005. Carcinoma of
unknown primary tumor was defined as a biopsy-proven
malignancy whose anatomical origin could not be identi-
fied by a conventional diagnostic workup (history, physi-
cal examination, laboratory tests, chest radiography, CT
of the chest, abdomen and pelvis, MRI of the suspected
lesion, endoscopic examinations where indicated, and, in
women, mammography). All patients had biopsy-proven
malignancies and the results of conventional diagnostic
examinations were negative. The workup performed was
determined based on the histological results, and there-
fore, the procedures used to detect the primary sites of
tumors differed among the patients.
PET or PET/CT imaging
All patients underwent whole-body 18F-fluorodeoxy-
glucose positron-emission tomography (18F-FDG PET)
or PET/CT scans according to the following procedure.
Patients were fasted for at least 8 h before receiving an
intravenous injection of 555-740 MBq(15-20 mCi; 0.22
mCi/kg body weight) of 18F-FDG. The uptake period
was 60-90 min. The PET was performed on a dedicated
PET scanner with a 5-min emission acquisition per ima-
ging level. Attenuation correction was performed using
the CT technique (140 kV, 80 mA) in the case of the
PET/CT. PET images were reconstructed with a 128 ×
128 matrix, an ordered subset expectation maximum
iterative reconstruction algorithm (six iterations, 16 sub-
sets), a 2-mm Shepp filter and a 16.2-cm field of view.
PET/CT images were reconstructed with a 144 × 144
matrix and a 3 D row action maximum likelihood algo-
rithm (two iterations, 0.006 relaxations). The results of
PET or PET/CT scans were evaluated by two experi-
enced nuclear medicine physicians that were unaware of
the histology of the metastatic sites.
Evaluation
’Detection of the primary tumor using PET or PET/CT’
was defined when additional information about the pri-
mary tumor was revealed by PET or PET/CT imaging.
Although the suspected primary site was seen on the
PET or PET/CT, it was not considered ‘detection by
PET or PET/CT’ if the suspected primary site was seen
on other imaging modalities such as the CT. When the
FDG uptake site in the PET or PET/CT was confirmed
as a benign lesion, this was defined as a ‘false positive’
PET or PET/CT result.
Results
Twenty patients (nine men and eleven women) were
included in the study. The median age was 54 years and
the mean follow-up duration was 26.5 months. Metas-
tases were located in the cervical lymph nodes (n =6 ) ,
bones (n = 4), abdominal lymph nodes (n = 3), axillary
lymph nodes (n =2 ) ,b r a i n( n =1 ) ,s k i n( n = 1), omen-
tum (n = 1), peritoneum (n = 1), and ureters (n =1 ) .
The histological findings were distributed as follows:
poorly differentiated carcinoma (n =1 1 ) ,a d e n o c a r c i -
noma (n = 5), squamous cell carcinoma (n =2 ) ,s i g n e t
ring cell carcinoma (n = 1), and leiomyosarcoma (n =1 )
(Table 1).
Among the 20 patients, 11 underwent 18F-FDG PET
scans, four of whom also underwent PET/CT scans sev-
eral months after the initial PET scan was performed.
The remaining nine out of the 20 patients only had a
PET/CT. Data on the 20 patients are shown in Table 2.
Neither the PET nor PET/CT detected the putative pri-
mary site of the metastatic tumor in any of the 20
patients. In six cases, the initial presentation was cervical
lymph node metastasis. Neither the PET nor PET/CT
detected the primary site of cervical lymph node metas-
tases. A 54-year-old male (patient no. 9) presented with
right cervical lymph node metastasis from an unknown
primary tumor. The patient had a radical neck dissec-
tion, unilateral tonsillectomy, blind biopsy of the naso-
pharynx and the tongue base. The pathology revealed
metastatic squamous cell carcinoma in one out of 20
Table 1 Baseline characteristics of patients included in
the study
Variables n =2 0
Sex, male/female 9/11
Age, median (range) 54 (20-74)
Mean follow-up duration (months) 26.5
Site of metastases
Cervical LN 6
Extracervical LN (abdominal LN, axillary LN) 5 (3, 2)
Bone 4
Brain 1
Others* 4
Pathologic type
Poorly differentiated carcinoma 11
Adenocarcinoma 4
Squamous cell carcinoma 2
Signet ring cell carcinoma 2
Leiomyosarcoma 1
*skin, mesentery, peritoneum, ureter.
Abbreviation: LN = lymph node.
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Patient
no.
Sex Age Site of
metastases
Pathology PET or
PET/CT
PET or PET/CT finding Primary
site
detected
by IHC
IHC markers
used to
detect
primary site
Primary
tumor
Known
metastases
Additional
findings
Results of
additional
findings
1 M 54 Cervical LN Squamous cell
ca.
PET not seen seen - - - -
2 F 66 Bone PD PET/CT not seen seen - - - Vimentin, CK 7,
CK 20, CD 68
3 M 55 Cervical LN PD PET®PET/
CT
not seen seen - - - CK 7, CK 19,
CK 20,
Thyroglobulin,
4 F 57 Bone Signet ring cell
ca.
PET/CT not seen seen Neck, thyroid,
hand, forearm
uptake
Benign - CK 7, CK 20,
TTF-1,
ER, PR
5 M 56 Skin Adenocarcinoma PET®PET/
CT
not seen not seen Mid-esophagus
uptake
(subcarinal LN)
Benign - CK 7, CK 19,
CK 20
TTF-1
6 F 36 Bone Adenocarcinoma PET not seen seen - - Breast ER, PR, C-
erbB2,
CK 7, CK 20,
TTF-1, GCDFP-
15
7 F 62 Abdominal
LN
PD PET/CT not seen seen Pharynx,
thyroid, uptake
Benign - -
8 M 15 Cervical LN PD PET not seen seen - - - CK, Vimentin,
CD 68
9 M 54 Cervical LN Squamous cell
ca.
PET/CT not seen seen - - - -
10 M 46 Brain Leiomyosarcoma PET®PET/
CT
not seen seen Left lower lung
uptake
Benign - CD 34,
Smooth
muscle actin,
CD 68
11 F 34 Cervical LN PD PET not seen seen - - Lung CK 7, CK 20,
TTF-1
12 F 60 Omentum Adenocarcinoma PET/CT not seen * * * - CK7, CK 20
13 F 48 Peritoneum Adenocarcinoma PET/CT not seen seen Inguinal LN
uptake
Malignant - CK7, CK 20
14 F 60 Axillary LN PD PET not seen seen - - - CK 7, CK 20,
TTF-1
15 M 61 Cervical LN PD PET®PET/
CT
not seen seen - - - CK, leukocyte
common
antigen
16 F 53 Ureter PD PET/CT not seen * * * - CK 7, CK 20
17 M 59 Abdominal
LN
Adenocarcinoma PET/CT not seen seen Thyroid uptake Benign - CK 7, CK 19,
CK 20, TTF-1
18 M 68 Abdominal
LN
PD PET not seen * * * - CD 56, CK
19 F 51 Axillary LN PD PET/CT not seen seen - - - CK 7, CK 20,
TTF-1
20 F 43 Bone PD PET not seen seen Neck LN uptake Malignant - CK 7, CK 20
*PET or PET/CT was done several months later at the time of the initial workup.
Abbreviation: LN = lymph node., ca. = carcinoma, PD = poorly differentiated carcinoma, CT = computed tomography, PET = positron-emission tomography, IHC =
immunohistochemistry, ER = estrogen- receptor, PR = progesterone- receptor, CK = cytokeratin, TTF-1 = thyroid transcription factor-1, GCDFP-15 = gross cystic
disease.
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of malignancy in the other tissues including tonsil, ton-
gue base, parotid gland, salivary gland, and nasopharynx.
The PET/CT showed a hypermetabolic lesion (SUV
13.0) in a right cervical lymph node, at level II. How-
ever, there was no additional FDG uptake suggesting a
primary site (Figure 1). These findings contrast with
those of previous studies [6,10-12] that demonstrated
the efficacy of PET for localizing primary sites of cervi-
cal lymph node metastases. In this study, not even the
PET/CT was able to localize the primary site of the cer-
vical lymph node metastases.
The PET or PET/CT revealed FDG-uptake lesions
o t h e rt h a nt h ek n o w nm e t a s t a s e si ns e v e no u to f2 0
patients. Five lesions were confirmed as benign (false
positive results), and two were pathologically confirmed
as another metastatic lesion after biopsy. Three out of
five false positive cases (patients no. 4, 7, and 17) also
displayed FDG uptake by the thyroid or pharynx (stan-
dardized uptake value [SUV] = 2.9-7.1); in patients
where the initial physical examinations showed normal
thyroids and pharynxes. Clinically, these thyroid glands
and pharynxes were not considered to be the primary
tumors and did not exhibit malignant changes during
the follow-up period.
In two out of five false positive cases, the results of
the scans were initially thought to show the primary
tumors and a diagnostic workup of these patients was
expanded to include invasive procedures. For example,
one patient (patient no. 5) with a metastatic adenocarci-
noma of the skin had additional FDG uptake around the
mid-esophagus (SUV 8.9). To confirm this lesion, the
patient underwent a repeat esophagogastroduodeno-
scopy (Initial result of endoscopy was negative.); how-
ever, there was no evidence of a malignancy in the
esophagus. A mid-esophagus lesion was observed as
subcarinal lymph node uptake on a subsequent chest
CT. Because the follow up PET/CT scan showed
decreased size and FDG uptake of the subcarinal lymph
node, this lesion was confirmed to be a benign lesion.
Another patient, with metastatic leiomyosarcoma of the
brain (patient no. 10) had mild hypermetabolic findings
in the lower left lung field. Because a malignancy could
not be ruled out, the patient underwent bronchoscopy
and a chest CT. There was no evidence of a malignancy.
Because of the false positive PET result, the patient had
unnecessary invasive procedures.
In two patients (patient no. 13 and 20) out of the
seven that had additional FDG uptake, other metastatic
lesions were confirmed by pathological examination of
biopsies. Because these metastatic sites were just addi-
tional, the management plans of these patients did not
change. The results with additional FDG uptake did not
positively influence the management and therapeutic
plans of the patients.
In four cases, the PET/CT was performed after the
initial PET scan (patient no. 3, 5, 10 and 15). The PET/
CT, which is anatomically more accurate than the PET,
did not confer any additional advantage in the detection
of the primary sites of patients with CUP.
Discussion
Detection of the primary tumor can change the prog-
nosis of patients with CUP by enabling targeted treat-
ment. Previous studies have indicated that PET and
PET/CT are useful for the detection of primary sites
[7,8,13-15]. In this study, neither the PET nor PET/CT
imaging improved the detection of the putative primary
sites in patients with CUP that already had thorough
conventional diagnostic workups. Neither PET nor PET/
CT detected the primary sites in any of the 20 patients
with CUP.
Previous studies have reported that PET detects pri-
mary lesions in 24%-41% of patients with CUP [7].
However, these studies differ in the definition of patients
with CUP and conventional workups. Lassen et al. [16]
identified primary cancers in nine out of 20 patients
Figure 1 A 54-year-old male with right cervical lymph node
metastasis from an unknown primary tumor (patient 9): The
patient had radical neck dissection, tonsillectomy, blind biopsy
of the nasopharynx and tongue base. The pathology revealed
metastatic squamous cell carcinoma in one out of 20 lymph nodes.
However, there was no evidence of malignancy in other tissues
including tonsiles, tongue base, parotid gland, salivary gland, or
nasopharynx; (A) PET/CT showed a hypermetabolic lesion (SUV 13.0)
in right cervical lymph node(arrow) at level II; (B) There was no
additional FDG uptake suggesting a primary site in the transaxial
PET/CT scans of the chest and pelvis.
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eight patients had primary lung cancers and did not
undergo chest CTs during the conventional workups.
Bohuslavizki et al. [17] studied 53 patients with CUP, of
whom primary tumor sites were detected in 20 (37.8%)
using the PET. This study did not include CT or mag-
netic resonance imaging (MRI) in the conventional
workup. Alberini et al. [18] investigated 41 patients with
CUP. PET detected primary sites in 26 patients; how-
ever, 15 patients had the primary site revealed in the
conventional workup. The results of previous studies
differed from the findings of this study, which was
limited to patients for whom a complete conventional
workup, including CT or MRI of suspected lesions,
failed to show a primary lesion.
According to the previous literature [2], 20-27% of
primary sites are identified before the patients with CUP
die. The primary site was not initially identified in all of
our study patients and was detected in 2 of 20 cases by
immunohistochemical staining of biopsied metastatic
lesions during the follow-up period. We included only
patients whose primary sites were not identified by
initial complete diagnostic workups including CT of
chest, abdomen, pelvis and endoscopic examinations.
Therefore, the patients in our study might have less
chance to detect primary sites.
The poor resolution of PET has been superseded by
PET/CT, which identifies anatomical landmarks more
accurately. The PET/CT detects the primary tumor in
22-73% of patients with CUP, according to a recent
review article [8]. However, in our study PET/CT did
not improve the detection rate of primary sites in
patients with CUP. The findings are consistent with
those reported by Gutzeit et al.[14] that the identifica-
tion rate of primary cancers using PET/CT was 33%,
but the diagnostic accuracy did not differ significantly
from that of the other modalities even though it
revealed more anatomical detail.
The PET and PET/CT have gained widespread accep-
tance as useful methods for the management of cancer
[19]. However, they do not appear to be effective in
identifying a primary lesion after a thorough conven-
tional workup fails to do so. This may be due to the
biological characteristics of primary tumors. Primary
tumors may disappear after seeding metastases because
their angiogenetic incompetence leads to marked apop-
tosis and cell turnover [20]. Primary tumors that have
regressed would not be detected by PET or PET/CT. In
this study, neither the PET nor PET/CT detected pri-
mary sites in six patients with cervical lymph node
metastases, contrary to the findings of other studies
[6,12]. The 6 patients with cervical lymph node metas-
tases in this study included 4 poorly differentiated carci-
nomas and 2 squamous cell carcinomas. The metastases
of poorly differentiated carcinoma would have marked
cell turnover and apoptosis and that leads to early
regression of the primary site. A higher portion of
poorly differentiated carcinoma would be one reason for
a low detection rate of primary sites in cases with cervi-
cal lymph node metastases.
The PET or PET/CT revealed FDG uptake lesions
o t h e rt h a nt h ek n o w nm e t a s t a s e si ns e v e np a t i e n t s .
These additional uptake lesions were of no value for
detecting the primary sites of tumors, and false positive
FDG uptake lesions complicated the diagnosis. Despite
no additional value of the PET or PET/CT in the detec-
tion of the primary site, primary lesions were identified
in two cases by immunohistochemical staining of biop-
sied metastatic lesions during the follow-up period
(Table 2). Various immunohistochemical markers were
used to identify the primary site according to the
pathology of the metastatic sites. In one patient (patient
no. 6) with metastatic adenocarcinoma, immunohisto-
chemical markers such as the estrogen-receptor, proges-
terone-receptor, C-erbB2, cytokeratin 7, cytokeratin 20,
TTF-1(Thyroid Transcription Factor-1) and GCDFP-15
(Gross Cystic Disease Fluid Protein 15) were used to
identify the primary site. Immunohistochemical staining
for the estrogen-receptor, progesterone-receptor and C-
erbB2 were positive, but cytokeratin 7, cytokeratin 20,
TTF-1 and GCDFP-15 were negative. Therefore, the pri-
mary cancer was presumed to be a breast cancer. Cyto-
keratin 7, cytokeratin 20 and TTF-1 were used in a
patient with cervical lymph node metastasis (patient no.
11). Results of immunohistochemical staining showed
positive cytokeratin 7, negative cytokeratin 20 and focal
positive TTF-1 in this patient. The primary cancer was
presumed to be a non-small cell lung cancer. A careful
conventional workup that includes immunohistochemis-
try would be helpful for cases in which the primary site
cannot be successfully identified using PET or PET/CT.
PET or PET/CT scans are easy to perform because of
their non-invasiveness [5]; however, subsequent invasive
procedures and biopsies are inevitable for pathology
confirmation of the results of the PET and PET/CT.
The limitations of this study included the following.
First, the sample size was small and the study design
was retrospective. Second, this study was performed in
the early stages of PET and PET/CT, when the PET and
PET/CT were not widely used. It is possible that the
study results do not reflect current PET or PET/CT
scanning.
In conclusion, neither PET nor PET/CT improved the
detection of primary sites in patients with CUP in our
study. Although it is inconclusive because of small sam-
ple size of the study, the additional value of PET or
PET/CT for the detection of primary sites in patients
with CUP might be less than expected; especially in
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diagnostic workups. Further study is needed to validate
this finding.
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